Department of Neurosurgery, University Hospital of Lausanne (CHUV), University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Vaud, Switzerland.
Department of Intensive Care, University Hospital of Lausanne (CHUV), University of Lausanne, Lausanne, Vaud, Switzerland.
Acta Neurochir (Wien). 2024 Mar 12;166(1):133. doi: 10.1007/s00701-024-06023-z.
Intrathecal vasoactive drugs have been proposed in patients with aneurysmal subarachnoid hemorrhage (aSAH) to manage cerebral vasospasm (CV). We analyzed the efficacy of intracisternal nicardipine compared to intraventricular administration to a control group (CG) to determine its impact on delayed cerebral ischemia (DCI) and functional outcomes. Secondary outcomes included the need for intra-arterial angioplasties and the safety profile.
We performed a retrospective analysis of prospectively collected data of all adult patients admitted for a high modified Fisher grade aSAH between January 2015 and April 2022. All patients with significant radiological CV were included. Three groups of patients were defined based on the CV management: cisternal nicardipine (CN), ventricular nicardipine (VN), and no intrathecal nicardipine (control group).
Seventy patients met the inclusion criteria. Eleven patients received intracisternal nicardipine, 18 intraventricular nicardipine, and 41 belonged to the control group. No cases of DCI were observed in the CN group (p = 0.02). Patients with intracisternal nicardipine had a reduced number of intra-arterial angioplasties when compared to the control group (p = 0.03). The safety profile analysis showed no difference in complications across the three groups. Intrathecal (ventricular or cisternal) nicardipine therapy improved functional outcomes at 6 months (p = 0.04) when compared to the control group.
Administration of intrathecal nicardipine for moderate to severe CV reduces the rate of DCI and improved long-term functional outcomes in patients with high modified Fisher grade aSAH. This study also showed a relative benefit of cisternal over intraventricular nicardipine, thereby reducing the number of angioplasties performed in the post-treatment phase. However, these preliminary results should be confirmed with future prospective studies.
已有研究提出在蛛网膜下腔出血(aSAH)患者中鞘内给予血管活性药物以治疗脑血管痉挛(CV)。本研究分析了与对照组(CG)相比,鞘内给予尼卡地平对迟发性脑缺血(DCI)和功能结局的影响,并评估了其疗效。次要结局包括需要进行动脉内血管成形术和安全性。
我们对 2015 年 1 月至 2022 年 4 月间所有因高改良 Fisher 分级 aSAH 入院的成年患者前瞻性收集的数据进行了回顾性分析。所有有明显 CV 影像学证据的患者均被纳入。根据 CV 治疗方法将患者分为三组:鞘内尼卡地平(CN)组、脑室尼卡地平(VN)组和未鞘内给予尼卡地平的对照组(CG)。
70 例患者符合纳入标准。11 例患者接受了鞘内尼卡地平治疗,18 例患者接受了脑室尼卡地平治疗,41 例患者属于对照组。CN 组未观察到 DCI 病例(p=0.02)。与 CG 相比,CN 组患者需要进行的动脉内血管成形术数量更少(p=0.03)。三组患者的安全性分析结果无差异。与 CG 相比,鞘内(脑室或鞘内)给予尼卡地平治疗可改善 6 个月时的功能结局(p=0.04)。
对于中重度 CV,鞘内给予尼卡地平可降低高改良 Fisher 分级 aSAH 患者的 DCI 发生率,并改善长期功能结局。本研究还表明,鞘内给予尼卡地平较脑室给予尼卡地平具有相对优势,可减少治疗后阶段进行的血管成形术数量。然而,这些初步结果需要未来的前瞻性研究进一步证实。